Trial reportThe European respiratory journal2013
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.
Trial report in The European respiratory journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00930982 (Randomized, Placebo-controlled, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhale Compared to Placebo in Patients With Non-cystic Fibrosis Bronchiectasis), which is not on this map. Cited by 65 papers, 13 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Placebo-controlled, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhale Compared to Placebo in Patients With Non-cystic Fibrosis Bronchiectasis
Who cites it
65 citing papers in PubMed, 13 syntheses or guidelines pooled it, 200 citations in OpenAlex.
- Management of Adult Bronchiectasis: Consensus-Based Guidelines of the German Respiratory Society.Respiration; international review of thoracic diseases · 2026Guideline
- Pooled it
- Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis.The European respiratory journal · 2021Pooled it
- A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults.European respiratory review : an official journal of the European Respiratory Society · 2019Pooled it
- Continuous versus intermittent antibiotics for bronchiectasis.The Cochrane database of systematic reviews · 2018Pooled it
- Oral versus inhaled antibiotics for bronchiectasis.The Cochrane database of systematic reviews · 2018Pooled it
- Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.Chronic respiratory disease · 2017Pooled it
- Interventions for enhancing adherence to treatment in adults with bronchiectasis.The Cochrane database of systematic reviews · 2015Pooled it
- Distribution of Major Pathogens from Sputum and Bronchoalveolar Lavage Fluid in Patients with Noncystic Fibrosis Bronchiectasis: A Systematic Review.Chinese medical journal · 2015Pooled it
- Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.The Cochrane database of systematic reviews · 2015Pooled it
- Interventions for bronchiectasis: an overview of Cochrane systematic reviews.The Cochrane database of systematic reviews · 2015Pooled it
- Efficacy of inhaled ciprofloxacin agents for the treatment of bronchiectasis: a systematic review and meta-analysis of randomized controlled trials.Therapeutic advances in respiratory diseasePooled it
- Inhaled antibiotics therapy for stable non-cystic fibrosis bronchiectasis: a meta-analysis.Therapeutic advances in respiratory diseasePooled it
- Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.American journal of respiratory and critical care medicine · 2014Trial
- Trial
- Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.Clinical drug investigation · 2013Trial
- Characterising research trends in bronchiectasis through AI-powered analytics.The European respiratory journal · 2025Review
- Comparative efficacy and safety of inhaled antibiotics in managing chronicJournal of thoracic disease · 2025Article
- Utilization of Inhaled Antibiotics in Pediatric Non-Cystic Fibrosis Bronchiectasis: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2025Review
- Targeting neutrophil serine proteases in bronchiectasis.The European respiratory journal · 2025Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This phase II, randomised, double-blind, multicentre study (NCT00930982) investigated the safety and efficacy of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis. Adults who were culture positive for pre-defined potential respiratory pathogens (including Pseudomonas aeruginosa and Haemophilus influenzae) were randomised to ciprofloxacin DPI 32.5 mg or placebo administered twice daily for 28 days (with 56 days of follow-up). Bacterial density in sputum (primary end-point), pulmonary function tests, health-related quality of life and safety were monitored throughout the study. 60 subjects received ciprofloxacin DPI 32.5 mg and 64 received placebo. Subjects on ciprofloxacin DPI had a significant reduction (p<0.001) in total sputum bacterial load at the end of treatment (-3.62 log10 CFU·g(-1) (range -9.78-5.02 log10 CFU·g(-1))) compared with placebo (-0.27 log10 CFU·g(-1) (range -7.96-5.25 log10 CFU·g(-1))); the counts increased thereafter. In the ciprofloxacin DPI group, 14 (35%) out of 40 subjects reported pathogen eradication at end of treatment versus four (8%) out of 49 in the placebo group (p=0.001). No abnormal safety results were reported and rates of bronchospasm were low. Ciprofloxacin DPI 32.5 mg twice daily for 28 days was well tolerated and achieved significant reductions in total bacterial load compared with placebo in subjects with non-cystic fibrosis bronchiectasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.